Search found 2904 matches
- Mon Mar 05, 2018 8:27 am
- Forum: Campath (Lemtrada, Alemtuzumab)
- Topic: Third course of Lemtrada improves MS patient’s relapse rate
- Replies: 0
- Views: 4532
Third course of Lemtrada improves MS patient’s relapse rate
Study shows third course of Lemtrada improves MS patient’s relapse rate and disability A study released at #ACTRIMS2018 has revealed that patients who experienced relapses after two courses of Lemtrada (alemtuzumab) showed improvement in relapse rate and disability progression after a third course o...
- Fri Mar 02, 2018 6:45 am
- Forum: General Discussion
- Topic: Daclizumab (Zinbryta) is withdrawn from the European market
- Replies: 1
- Views: 1423
Daclizumab (Zinbryta) is withdrawn from the European market
Germany recently informed the European Medicines Agency (EMA) that seven patients with multiple sclerosis (MS) had developed immune-mediated inflammation of the brain (encephalitis) during treatment with daclizumab beta (Zinbryta). Three of these patients also had a severe allergic reaction (drug re...
- Fri Mar 02, 2018 3:00 am
- Forum: General Discussion
- Topic: Eating fish may be tied to a reduced risk of MS
- Replies: 2
- Views: 1594
Eating fish may be tied to a reduced risk of MS
Eating fish at least once a week or eating fish one to three times per month in addition to taking daily fish oil supplements may be associated with a reduced risk of multiple sclerosis (MS), according to a preliminary study released that will be presented at the American Academy of Neurology's 70th...
- Tue Feb 27, 2018 2:20 am
- Forum: General Discussion
- Topic: Progress on the legalisation of medical cannabis...
- Replies: 2
- Views: 1679
Progress on the legalisation of medical cannabis...
Progress on the legalisation of medical cannabis takes a side step On Friday 23 February, the United Patients Alliance gathered for another peaceful protest outside the House of Parliament while the second reading of the Emily Brice bill took place…Read more - http://www.ms-uk.org/progress-legalisat...
- Wed Feb 21, 2018 4:54 am
- Forum: General Discussion
- Topic: Study - 93.7% improvement in patients treated with cannabis
- Replies: 0
- Views: 1652
Study - 93.7% improvement in patients treated with cannabis
Study highlights 93.7% improvement in patients treated with cannabis In recent years there has been a substantial increase in the use of medical cannabis, particularly with the aging population. In a recent study, titled “Epidemiological characteristics, safety and efficacy of medical cannabis in th...
- Tue Feb 20, 2018 5:44 am
- Forum: Tysabri (Antegren, Natalizumab)
- Topic: Risks associated between MS drug natalizumab and pregnancy
- Replies: 0
- Views: 3375
Risks associated between MS drug natalizumab and pregnancy
Study reveals the risks associated between MS drug natalizumab and pregnancy A recent study, published in the journal Neurology, assessed foetal risk after pregnancy exposure to natalizumab (Tysabri) in women with multiple sclerosis (MS). The Italian study specifically focused on spontaneous abortio...
- Wed Feb 14, 2018 6:13 am
- Forum: General Discussion
- Topic: Higher dose of MS drug Glatopa finally gets US approval
- Replies: 0
- Views: 2007
Higher dose of MS drug Glatopa finally gets US approval
Sandoz, a Novartis division, has announced US Food and Drug Administration (FDA) approval and launched a 40 mg/ml dose of Glatopa, a glatiramer acetate injection…Read more - http://www.ms-uk.org/higher-dose-ms-drug-glatopa-finally-gets-us-approval https://scontent-lht6-1.xx.fbcdn.net/v/t1.0-9/261688...
- Wed Feb 14, 2018 6:11 am
- Forum: Mavenclad (Cladribine)
- Topic: Cladribine gets approval in Scotland
- Replies: 0
- Views: 2650
Cladribine gets approval in Scotland
NHS Scotland has accepted cladribine (Mavenclad) as a treatment option for people with highly active multiple sclerosis (MS) living in Scotland… http://www.ms-uk.org/cladribine-gets-approval-scotland https://scontent-lht6-1.xx.fbcdn.net/v/t1.0-9/26168845_1680181818687432_2707888596679484414_n.png?oh...
- Tue Feb 13, 2018 5:17 am
- Forum: General Discussion
- Topic: Experimental therapy restores nerve insulation damage
- Replies: 0
- Views: 1850
Experimental therapy restores nerve insulation damage
Experimental therapy restores nerve insulation damage caused by autoimmune conditions When the body attacks its own healthy tissues in an autoimmune condition, peripheral nerve damage disable people and causes persistent neuropathic pain when insulation on healing nerves doesn't fully regenerate…Rea...
- Wed Feb 07, 2018 3:21 am
- Forum: Tysabri (Antegren, Natalizumab)
- Topic: Changing natalizumab dosing frequency reduced risk for PML
- Replies: 1
- Views: 3465
Changing natalizumab dosing frequency reduced risk for PML
Changing natalizumab dosing frequency reduced risk for Progressive Multifocal Leukoencephalopathy (PML) A commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS sp...
- Wed Feb 07, 2018 1:28 am
- Forum: General Discussion
- Topic: Family Planning among Women with Relapsing MS
- Replies: 0
- Views: 1325
Family Planning among Women with Relapsing MS
Survey Highlights Misconceptions about Family Planning among Women with Relapsing Forms of Multiple Sclerosis Of 1,000 women diagnosed with relapsing remitting multiple sclerosis (RRMS) in the last five years, 88% were concerned they would not be able to have children, despite studies that show othe...
- Fri Feb 02, 2018 5:51 am
- Forum: General Discussion
- Topic: Ibudilast 26% reduction in confirmed disability progression
- Replies: 0
- Views: 1427
Ibudilast 26% reduction in confirmed disability progression
MS drug ibudilast demonstrated a 26% reduction in confirmed disability progression in progressive MS trial Biopharmaceutical Company MediciNova has announced additional positive clinical data from its SPRINT-MS phase IIB trial of MN-166 (ibudilast) in progressive multiple sclerosis (PMS)...Read more...
- Thu Feb 01, 2018 7:29 am
- Forum: General Discussion
- Topic: Balance and eye-movement exercises could help people with MS
- Replies: 0
- Views: 1369
Balance and eye-movement exercises could help people with MS
According to a study, published in the 31 January 2018 online edition of Neurology, the medical journal of the American Academy of Neurology, a special programme of balance and eye movement exercises may help people with multiple sclerosis (MS)... Read more - http://www.ms-uk.org/balance-and-eye-mov...
- Mon Jan 29, 2018 1:44 am
- Forum: General Discussion
- Topic: Holland approves cannabis chewing gum development programme
- Replies: 0
- Views: 1618
Holland approves cannabis chewing gum development programme
The Dutch Medicines Evaluation Board has signed off AXIM Biotechnologies’ MedChew Rx clinical development programme, which will see them develop and trial a cannabis based chewing gum…Read more - http://www.ms-uk.org/holland-approves-cannabis-chewing-gum-development-programme https://scontent-lht6-1...
- Thu Jan 25, 2018 6:54 am
- Forum: Gilenya
- Topic: Gilenya withdrawal may trigger the return of disease act.
- Replies: 0
- Views: 5685
Gilenya withdrawal may trigger the return of disease act.
Gilenya withdrawal may trigger the return of pre-treatment disease activity It is difficult to identify patients at risk of disease reactivation. So in a recent study scientists at Cerrahpasa School of Medicine, Istanbul University in Turkey compared the demographic and clinical features of patients...